Importance: This study addresses the critical need for an evidence-based instrument to assess the likelihood of NSAID-induced cardiovascular events, that provides clinicians with valuable decision support to improve safety in their use for pain management, especially in patients vulnerable to cardiovascular events.
Objective: To develop a practical risk scoring tool, NSAID Induced Cardiovascular Events (NAÏVE), for estimating the risk of serious cardiovascular events associated with NSAID use.
Design: Retrospective nested case-control study.
Setting: The study leveraged data from the DAVINCI database, integrating electronic health records, administrative data, and clinical data from both the Veterans Health Administration (VHA) and the Department of Defense (DoD).
Participants: The study cohort consisted of individuals with at least one NSAID pharmacy claim, with cases defined as those experiencing non-fatal myocardial infarction, non-fatal stroke, or new heart failure.
Interventions: Development of the NAÏVE risk scoring tool involved a comprehensive analysis of demographic, clinical, and prescription-related variables, including NSAID exposure, comorbidities, and medication history.
Main Outcomes/measures: The primary outcome was the first occurrence of a cardiovascular event.
Results: The study cohort comprised 231,967 cases and 2,319,670 controls, identified from individuals with at least one NSAID pharmacy claim between October 1, 2016, and September 30, 2020. The risk index, NAÏVE, demonstrated strong discriminatory ability and calibration, with a C-statistic of 0.88. Variables such as age, NSAID exposure, comorbidities, and medication history were associated with increased odds of NSAID-induced cardiovascular events.
Conclusions/relevance: NAÏVE is the first evidence-based risk scoring tool providing clinicians with valuable decision support for assessing the potential risk of serious cardiovascular events associated with NSAID use. It fills a crucial gap in clinical practice, allowing for transparent discussions with patients and shared decision-making regarding NSAID prescriptions. Further validation and prospective testing are warranted for broader applicability.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892502 | PMC |
| http://dx.doi.org/10.2147/JPR.S503743 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cumulative blood pressure predicts risk of cardiovascular outcomes in middle-aged and older population.
Ann Med
December 2025
Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China.
Background: Cardiovascular disease (CVD) remains a major health concern globally, contributing to a considerable disease burden. However, few studies have considered long-term cumulative blood pressure (cBP) exposure in middle-aged and older population in China. The aim of this study was to investigate whether long-term cBP was associated with subsequent cardiovascular outcomes among participants without CVD at baseline in Chinese over 45 years old.
View Article and Find Full Text PDFMacitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension Study.
Circ Heart Fail
March 2025
Department of Medicine, University of Maryland School of Medicine, Baltimore (M.T.G.).
Background: Despite favorable hemodynamic and neurohormonal effects, endothelin receptor antagonists have not improved outcomes in patients with heart failure (HF), possibly because they cause fluid retention.
Methods: In this randomized, double-blind, multicenter trial (SERENADE [Macitentan in Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease]), we evaluated the effects of an endothelin receptor antagonist, macitentan, in patients with HF, left ventricular ejection fraction ≥40%, and pulmonary vascular disease. After a 4-week placebo run-in (to ensure clinical stability), followed by a 5-week single-blind macitentan run-in, patients who did not exhibit fluid retention were randomized to macitentan or placebo.
Impact of diabetes on risk of major adverse cardiovascular events associated with lipoprotein(a) levels in patients with established atherosclerotic cardiovascular disease.
Eur J Prev Cardiol
March 2025
Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-gu, Seoul 05505, Republic of Korea.
Aims: Lipoprotein(a) [Lp(a)] is an emerging risk factor for major adverse cardiovascular events (MACE). However, evidence on MACE risk according to Lp(a) level in atherosclerotic patients is insufficient, and more data is needed about whether type 2 diabetes (T2DM) additionally contributes to this risk. We aimed to investigate the association between Lp(a) and MACE in atherosclerotic patients and compare the magnitude of Lp(a)-MACE association in the patients with and without T2DM.
View Article and Find Full Text PDFAssociation between estimated glucose disposal rate and incident cardiovascular disease in a population with Cardiovascular-Kidney-Metabolic syndrome stages 0-3: insights from CHARLS.
Front Cardiovasc Med
February 2025
The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, China.
Objective: Estimated glucose disposal rate (eGDR) is a reliable marker of insulin resistance (IR), which has been proven to be strongly linked to cardiovascular and renal diseases. However, the link between eGDR and the occurrence of cardiovascular disease (CVD) in individuals exhibiting Cardiovascular-Kidney-Metabolic (CKM) syndrome stages 0-3 remains ambiguous.
Methods: The data employed in this investigation was procured from the China Health and Retirement Longitudinal Study (CHARLS).
Intraprocedural activated clotting time and heparin dosage in pulsed field ablation of paroxysmal atrial fibrillation.
Front Cardiovasc Med
February 2025
Department of Cardiology, Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Aims: Whether the intraprocedural anticoagulation regimen and activated clotting time (ACT) in pulsed field ablation (PFA) for atrial fibrillation (AF) are the same as those for radiofrequency catheter ablation (RFCA) is currently unknown.
Methods And Results: Our retrospective study included 51 paroxysmal AF patients who underwent PFA (PFA group) and were matched with paroxysmal AF patients who underwent RFCA. Nearest-neighbor propensity score matching was performed at a 1:1 ratio (no tolerance to anticoagulant regimens and a tolerance of 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!